poisar

Stocks · News reference

AbbVie Submits EMA Application For SKYRIZI Subcutaneous Induction In Adults With Moderately To Severely Active Crohn's Disease, Backed By Phase 3 AFFIRM Data

Aug 27, 2026, 6:25 AMBenzinga Newsdesk

Submission supported by data from Phase 3 pivotal AFFIRM studyIf approved, adult Crohn's disease patients will have an additional option for induction of risankizumab which is already approved for intravenous (IV)

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBV
Source
benzinga
Observed
Aug 27, 2026, 6:25 AM
Checked
Aug 27, 2026, 6:25 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 26, 2026, 10:20 AMDave Kovaleski

    Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.

    Billionaire hedge fund manager Ken Griffin's Citadel increased its stake in AbbVie by 547% in Q2, adding 2.7 million shares worth approximately $798 million. The move reflects a defensive investment strategy into a stable dividend stock. AbbVie, a Dividend King with 54 consecutive years of dividend increases, currently yields 2.6% and has 75% of Wall Street analysts rating it as a buy with a median price target of $282.50.

    Read original at the-motley-fool
    ABBVABT
  2. Aug 24, 2026, 2:15 PMMicah Zimmerman

    Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.

    Billionaire hedge fund manager Ken Griffin recently increased his stakes in AbbVie and Abbott Laboratories through his fund Citadel. The article analyzes whether retail investors should follow his lead, highlighting AbbVie's transition from Humira to new immunology drugs like Skyrizi and Rinvoq with expansion into oncology, and Abbott's strong positions in diabetes care, diagnostics, and medical devices. The author suggests both stocks merit consideration as part of a long-term healthcare allocation based on their business fundamentals rather than simply following Griffin's moves.

    Read original at the-motley-fool
    ABBVABT